Expert Details
Neuroscience, Auto-Immune Drug Development, and the CDMO Sector
ID: 739654
United Kingdom
Expert offers unrivalled experience in CDMO's (contract development and manufacturing organizations). He currently holds a leadership role in the commercial development of a novel asset for the treatment of several rare auto-immune indications. He is currently working in an Advisory Pharmaceutical Consultancy role on CMC and Corporate Strategy. In this role, he leverages expertise in CDMO & Neurology, providing ongoing consultations with blue chip clients including E&Y, Mckinsey and investment banks.
He possesses a deep appreciation of the inevitable trade-offs in drug development -- e.g., speed to market vs. asset differentiation). He established the competitive intelligence function at mid-size European pharma company. He has also served as strategic partner for the company's Alzheimer disease program, where he delivered insights impacting decision making and investment options for the therapy area.
Expert has also been a principal consultant to global pharmaceutical contract manufacturers on corporate strategy, manufacturing demand, and competitor positioning. He was responsible for building a boutique consultancy that counted 8 of the 10 leading CDMOs as clients, increasing sales over five fold. During this time he was a keynote speaker at industry events. He was an advisor on market entry strategy to GSK on contract manufacturing.
He has 10 publications, and is the an author of definitive industry reports, leveraging new and unparalleled data resources for consultancy, propelling Strategic Advantage Database into the premier intelligence platform.
He received his Doctor of Philosophy in MRC Anatomical Neuropharmacology from the University of Oxford, His Masters of Science in Management in Neuroscience from the Institute of Psychiatry at King's College London, his Bachelor of Science with honors in Biochemistry & Pharmacology from the University of Leeds, and his Diploma in Accounting & Finance from London Guildhall University.
Education
| Year | Degree | Subject | Institution |
|---|---|---|---|
| Year: 1994 | Degree: D.Phil | Subject: Neuroscience | Institution: University of Oxford |
| Year: 1990 | Degree: Msc | Subject: Neuroscience | Institution: Institute of Psychiatry, University of London |
Work History
| Years | Employer | Title | Department |
|---|---|---|---|
| Years: 2022 to Present | Employer: Undisclosed | Title: Advisory Pharmaceutical Consultancy on CMC and Corporate Strategy | Department: |
Responsibilities:Leveraging expertise in CDMO & Neurology, providing ongoing consultations with blue chip clients including E&Y, Mckinsey and investment banks.• Current epilepsy landscape, the transition to rare disease and the emergence of the digital ecosystem. • European Mid-cap R&D strategy, in-licensing, M&A rationale and company valuation. • Potential utility of Targeted protein degradation in haematological cancers; rationale, landscape and key companies • FcRN landscape, pre-clinical biology, strategic implications and the dynamics of market uptake across multiple indications • Trends in Blow-Fill Seal manufacturing; opportunities and competitive environment. • Market opportunity for selected high potent API manufacturing. • The CDMO sector, drivers, market dynamics & ROI by modality. Investment opportunities. |
|||
| Years | Employer | Title | Department |
| Years: 2018 to 2022 | Employer: UCB | Title: Director R&D Neurology | Department: Corporate Development & Finance |
Responsibilities:Challenger function, neuroscience expert providing Governance support to ExCom. A scientific and financial sparring partner aligning investments with business objectives, influencing senior stakeholders and UCB’s neuroscience strategy.• Head of commercial insight into early pipeline asset development for UCB0107 (Anti-Tau Mab in Alzheimer’s disease); spearheaded competitor intelligence, market landscape and therapy area overview for joint venture with Genentech, with end-to-end analysis for accelerated clinical programme for Bepranemab. • Strategic partner for Alzheimer disease, delivering insights impacting decision making and investment options for the therapy area. • Led review of UCB’s neuroscience strategy, challenging dependency on epilepsy portfolio. Questioned legacy decision-making, identifying protracted governance decisions and poor development timelines. • Partnered Licensing group to explore business development opportunities in epilepsy; accountable for long-term forecasting of epilepsy market and prospects for rare epilepsy acquisitions. • Initiated new benchmark programme of R&D productivity to estimate ROI against direct competitors. Analysed development performance in Myasthenia Gravis (endpoints and protocol amendments), identifying root causes of delays in clinical development strategy. • Challenged asset planning for Complement C5 peptide asset Zilucoplan across therapy areas, by identifying the risk of inappropriate launch analogues, leading to a revision of revenue forecasts and asset valuation. • Partnered Rare Disease business to develop auto-immune portfolio strategy, maximising asset differentiation in a crowded therapy class. Managed global qualitative and quantitative market research projects for Rozanolixizumab, to uncover trade-off decisions in formulation and drug development: • Designed Rozanolixizumab Go-to-market, a product strategy for the commercial launch of Rozimab in the EU, Japan and USA. Worked with global matrix of cross functional team members to develop country-level insights for the launch across multiple indications (device, Point of Care, reimbursement options and treatment trends). Assessed Rozanolixizumab, ITP: evaluating the feasibility of a patient Employer-monitoring device. • Developed a build vs. buy model for Gene Therapy questioning corporate assumptions on cost; recalibrated manufacturing (yield) estimates; timelines, with implications for key decision points in development and commercial strategy. • Led competitive intelligence for auto-immune and neurodegenerative therapies, including Alpha-synuclein assets UCB5099 and UCB7583, Bepranemab, and Rozanolixizumab. Accountable for insight generation including identifying key areas of uncertainty to business unit heads, deliverables to marketing, early-stage R&D and project management in Europe and USA. • Challenged existing company structure to compete more effectively with the new generation of highly capitalized Biopharma, proposing disruptive alternatives in Rare and Ultra Rare Diseases. |
|||
| Years | Employer | Title | Department |
| Years: 2012 to 2018 | Employer: Globaldata, PharmSource | Title: Director of Market Intelligence | Department: |
Responsibilities:Creator in Chief PharmSource Industry Intelligence, Consultancy, Strategic Advantage Database, Industry Trend Reports, Lead Sheet Strategy, and Editor.• Built the brand equity of PharmSource into a business acquired by AIM Listed GlobalData. • Grew Strategic Advantage subscriber base fivefold to over 65 clients and expanded subscriber revenue nine-fold to over $1.2 million in 5 years. • Principal consultant to global pharmaceutical contract manufacturers on corporate strategy, manufacturing demand, and competitor positioning. Advisor on market entry strategy to GSK on contract manufacturing; consultant to top 5 US contract manufacturers on M&A targets. • Strategic advisor to Lead Sheet (drug development portal), increasing revenue stream by 50% within 3 years. Editor of Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report, fee-based publications. |
|||
| Years | Employer | Title | Department |
| Years: 1999 to 2007 | Employer: Cardinal Health | Title: Senior Manager, Global Deputy Leader Strategic Intelligence | Department: Pharmaceutical Technologies & Services |
Responsibilities:Directed global biopharmaceutical market and competitor analysis in $2bn division: corporate and strategic planning, M&A, in-licensing.Corporate and Business Development, Competitive Intelligence • Market entry and portfolio expansion strategies for branded, bio-similar and hospital generics market with P&L models. • Due diligence on manufacturing opportunities in Eurasia, and in-licensing of oral technologies. • Strategic analysis of pipeline developments, pricing and reimbursement: improved forecasting, and market visibility. • Expanded proprietary biological manufacturing and $250m VMS unit. Senior Manager, Business Intelligence Europe $750m European division. • Designed partnering strategy for generics. • Conducted P&L analysis of in-licensing opportunities for proprietary manufacturing technologies. • Implemented global CRM project. • Advised C-suite on competitor entry, new drug performance, FDA product clearance and patent expiry. • Forecast European pipeline and Oral Technology revenue for capacity changes and capex spend; revenues and LOE in Zydis. Created award winning product screening process for fast dissolve technology. |
|||
Career Accomplishments
| Professional Appointments |
|---|
| Evaluate PLC, London Senior Pharmaceutical analyst University of Bristol. Dept. of Anatomy Post-Doctoral Research Neuroscience University of Birmingham. Dept. of Pharmacology Post-Doctoral Research Neuroscience |
| Publications and Patents Summary |
|---|
| 10 publications. Author of definitive industry reports, leveraging new and unparalleled data resources for consultancy, propelling Strategic Advantage Database into the premier intelligence platform, with subscribers including pharmaceutical companies, contractors, and top consultancies. |